Why the study?
Does aliskiren/amlodipine combination therapy reduce blood pressure in patients with moderate-to-severe hypertension compared with amlodipine monotherapy?
Population
n=485 patients with moderate-to-severe hypertension (mean sitting systolic blood pressure ≥ 160 to < 200 mmHg)
Comparison
Aliskiren/amlodipine combination therapy vs Amlodipine monotherapy
Design
RCT, randomised, double-blind
Follow-up
8 weeks
Authors
Loading...
Supports aliskiren/amlodipine combination as initial therapy for moderate-to-severe hypertension; extends monotherapy comparisons with direct RCT evidence.
Does aliskiren/amlodipine combination therapy reduce blood pressure in patients with moderate-to-severe hypertension compared with amlodipine monotherapy?
Aliskiren/amlodipine combination therapy provides significantly greater blood pressure reductions and higher control rates than amlodipine monotherapy in patients with moderate-to-severe hypertension.
Braun‐Dullaeus et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: